These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16439677)

  • 1. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
    Secchiero P; Barbarotto E; Tiribelli M; Zerbinati C; di Iasio MG; Gonelli A; Cavazzini F; Campioni D; Fanin R; Cuneo A; Zauli G
    Blood; 2006 May; 107(10):4122-9. PubMed ID: 16439677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.
    Zauli G; di Iasio MG; Secchiero P; Dal Bo M; Marconi D; Bomben R; Del Poeta G; Gattei V
    Curr Cancer Drug Targets; 2009 Jun; 9(4):510-8. PubMed ID: 19519319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
    Secchiero P; Voltan R; di Iasio MG; Melloni E; Tiribelli M; Zauli G
    Clin Cancer Res; 2010 Mar; 16(6):1824-33. PubMed ID: 20215548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
    Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
    Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.
    Coll-Mulet L; Iglesias-Serret D; Santidrián AF; Cosialls AM; de Frias M; Castaño E; Campàs C; Barragán M; de Sevilla AF; Domingo A; Vassilev LT; Pons G; Gil J
    Blood; 2006 May; 107(10):4109-14. PubMed ID: 16439685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
    Voltan R; Secchiero P; Corallini F; Zauli G
    Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
    Wang DM; Liu L; Fan L; Zou ZJ; Zhang LN; Yang S; Li JY; Xu W
    Cancer Biol Ther; 2012 Dec; 13(14):1522-8. PubMed ID: 23052131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
    Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Barbarotto E; Corallini F; Rimondi E; Fadda R; Mischiati C; Grill V; Vaccarezza M; Celeghini C
    J Cell Biochem; 2008 May; 104(2):595-605. PubMed ID: 18092340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
    Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
    Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.
    Agnoletto C; Melloni E; Casciano F; Rigolin GM; Rimondi E; Celeghini C; Brunelli L; Cuneo A; Secchiero P; Zauli G
    Oncotarget; 2014 Jun; 5(12):4347-60. PubMed ID: 24962518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
    Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
    Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.
    Secchiero P; Melloni E; Tiribelli M; Gonelli A; Zauli G
    J Leukoc Biol; 2008 Feb; 83(2):434-7. PubMed ID: 17998303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
    di Iasio MG; Norcio A; Melloni E; Zauli G
    Invest New Drugs; 2012 Dec; 30(6):2403-6. PubMed ID: 22238073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
    Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
    Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
    Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
    J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
    Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
    Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
    Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
    Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.